Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-279 in Subjects With Moderate-to-Severe Plaque Psoriasis
NCT06550076Phase 3Active, not recruiting
- Sponsor
- Takeda
- Start
- Sep 2024
- Primary completion
- Aug 2029
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of zasocitinib in plaque psoriasis, sponsored by Takeda. Started Sep 2024; status: active, not recruiting.
02
Drugs
zasocitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT06550076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06550076.